Viatris (Viatris) Total Revenue Growth Rate (Future 3Y To 5Y Est) : -0.73 (As of Apr. 27, 2024)

View and export this data going back to 1986. Start your Free Trial

What is Viatris Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Viatris's Total Revenue Growth Rate (Future 3Y To 5Y Est) is -0.73.

Competitive Comparison of Viatris's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Viatris's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.

Viatris (NAS:VTRS) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Viatris Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Viatris's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (Viatris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (NAS:VTRS) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Comparable Companies

Traded in Other Exchanges

MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany MYL:Austria

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Executives

Andrew Cuneo	officer: See Remarks	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Xiangyang (sean) Ni	officer: President, Greater China	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Leo Frans Groothuis	director	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Scott Andrew Smith	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elisha W Finney	director	C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Van Der Meer Mohr Pauline	director	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Menassie Taddese	officer: See Remarks	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Robert J Coury	director, officer: Executive Chairman	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
W Don Cornwell	director
Brian Roman	officer: Global General Counsel	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Anthony Mauro	officer: See Remarks	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
James M Kilts	director	120 PARK AVE, NEW YORK NY 10017
Melina E Higgins	director	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Ian C Read	director	PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Dillon Joellen Lyons	director	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HARTFORDSHIRE X0 AL 109UL